Standpoint Research Downgrades Hi Tech Pharmacal (HITK) to Hold
Tweet Send to a FriendGet Alerts HITK Hot Sheet
Price: $33.86 --0%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 3 | New: 2
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 3 | New: 2
Trade HITK Now!
Standpoint Research downgraded Hi Tech Pharmacal (NASDAQ: HITK) from Buy to Hold.
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $31.25 yesterday, with a 52 week range of $27.35-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $31.25 yesterday, with a 52 week range of $27.35-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
- Baird Downgrades Sonoco Products (SON) to Neutral
- Jefferies Boosts PT on Micron (MU) Post Q3; Sees 50% Upside
Create E-mail Alert Related Categories
DowngradesRelated Entities
Standpoint Research
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
